The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals revealed topline results from its Lugano trial, showing promising efficacy for sustained release tyrosine kinase inhibitors (TKIs) in the treatment of wet age-related macular degeneration (AMD).
President and CEO Jay S. Duker, M.D., discussed the findings in an interview with Retinal Physician, outlining the potential impact of long acting TKI therapies for patients. The interview highlights the ongoing advancements aimed at improving outcomes and reducing treatment burden for those with wet AMD. No additional financial details or timeline for future development were disclosed in the announcement.
View post on X Loading...
Earlier this year, Eyepoint Pharmaceuticals released topline results from its pivotal Phase 3 LUGANO trial of DURAVYU for wet AMD treatment, according to company statements (link). The company also reported Q2 2026 financial results and outlined recent strategic actions in a separate disclosure (link). These updates provide context for the ongoing development of its pipeline in ophthalmology.